Breaking News

Financial Report: Alkermes

May 23, 2013

Revenues up 25% in the quarter


4Q Revenues: $163.4 million (+25%)

4Q Earnings: $3.0 million (loss of $63.4 million 4Q12)

FY Revenues: $575.5 million (+48%)

FY Earnings: $25.0 million (loss of $113.7 million FY12)

Comments: Revenues from the company’s five key commercial products for the quarter grew 26% to $89.5 million. Results reflect the completion of the merger of Alkermes with Elan Drug Technologies (EDT) in Sept. 2011. For the year, revenues included $50.0 million of intellectual property license revenue unrelated to key development programs.
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus